BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 27562108)

  • 1. 2014 CRL Build Study of Life Insurance Applicants.
    Fulks M; Dolan VF; Stout RL
    J Insur Med; 2016; 46(1):13-9. PubMed ID: 27562108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum globulin predicts all-cause mortality for life insurance applicants.
    Fulks M; Stout RL; Dolan VF
    J Insur Med; 2014; 44(2):93-8. PubMed ID: 25816467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2014 CRL Blood Pressure Study of Life Insurance Applicants.
    Fulks M; Dolan VF; Stout RL
    J Insur Med; 2015; 45(1):17-27. PubMed ID: 27584805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scoring life insurance applicants' laboratory results, blood pressure and build to predict all-cause mortality risk.
    Fulks M; Stout RL; Dolan VF
    J Insur Med; 2012; 43(3):169-77. PubMed ID: 23451618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mortality Risk of Low BMI in Life Insurance Applicants.
    Rigatti SJ; Stout R
    J Insur Med; 2024 Jul; 51(1):8-16. PubMed ID: 38802091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemoglobin Screening Independently Predicts All-Cause Mortality.
    Fulks M; Dolan VF; Stout RL
    J Insur Med; 2015; 45(2):75-80. PubMed ID: 27584842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular risk factors, BMI and mortality in a cohort of Swiss males (1976-2001) with high-sum-assured life insurance cover.
    Baldinger B; Schwarz C; Jaggy C
    J Insur Med; 2006; 38(1):44-53. PubMed ID: 16642642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urine protein/creatinine ratio as a mortality risk predictor in non-diabetics with normal renal function.
    Fulks M; Stout RL; Dolan VF
    J Insur Med; 2012; 43(2):76-83. PubMed ID: 22876411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NT-proBNP as a predictor of all-cause mortality in a population of insurance applicants.
    Clark M; Kaufman V; Fulks M; Dolan VF; Stout RL
    J Insur Med; 2014; 44(1):7-16. PubMed ID: 25004594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. All-Cause Mortality for Life Insurance Applicants with a Family History of Coronary Artery Disease Before 60.
    Freitas SA; MacKenzie R; Wylde DN; Von Bergen J; Holowaty JC; Beckman M; Rigatti SJ; Gill S
    J Insur Med; 2018 Jan; 47(3):159-171. PubMed ID: 30192720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased mortality associated with elevated carcinoembryonic antigen in insurance applicants.
    Stout RL; Fulks M; Dolan VF; Magee ME; Suarez L
    J Insur Med; 2007; 39(4):251-8. PubMed ID: 18522142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Carcinoembryonic Antigen with Mortality in an Insurance Applicant Population.
    Rigatti SJ; Stout R
    J Insur Med; 2019; 48(1):24-35. PubMed ID: 31747325
    [No Abstract]   [Full Text] [Related]  

  • 13. All-Cause Mortality for Life Insurance Applicants with the Presence of Bundle Branch Block.
    Freitas SA; MacKenzie R; Wylde DN; Von Bergen J; Holowaty JC; Beckman M; Rigatti SJ; Zamarripa D; Gill S
    J Insur Med; 2019; 48(1):36-47. PubMed ID: 31219368
    [No Abstract]   [Full Text] [Related]  

  • 14. Trends in mortality of insurance applicants with HIV infection.
    Stout RL; Fulks M; Dolan VF
    J Insur Med; 2012; 43(2):67-75. PubMed ID: 22876410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. All-Cause Mortality for Life Insurance Applicants with a History of Prostate Cancer.
    Freitas SA; MacKenzie R; Wylde DN; Roudebush BT; Bergstrom RL; Holowaty JC; Beckman M; Rigatti SJ; Gill S
    J Insur Med; 2017; 47(2):95-106. PubMed ID: 29490159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changing the "Normal Range" for Blood Pressure from 140/90 to 130/Any Improves Risk Assessment.
    Fulks M; Stout RL; Dolan VF
    J Insur Med; 2015; 45(1):28-33. PubMed ID: 27584806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. All-Cause Mortality for Life Insurance Applicants with a History of Breast Cancer.
    Freitas SA; MacKenzie R; Wylde DN; Roudebush BT; Bergstrom RL; Holowaty JC; Hart A; Rigatti SJ; Gill S
    J Insur Med; 2017; 47(1):6-22. PubMed ID: 28836905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Laboratory and biometric predictors of cancer-related mortality in an insured population.
    Palmier J; Lanzrath BJ
    J Insur Med; 2012; 43(3):162-8. PubMed ID: 23451617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Liver Function Tests with Mortality in an Insurance Applicant Population.
    Rigatti SJ; Stout R
    J Insur Med; 2022 Jul; 49(3):172-182. PubMed ID: 36378891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mortality associated with bilirubin levels in insurance applicants.
    Fulks M; Stout RL; Dolan VF
    J Insur Med; 2009; 41(1):49-53. PubMed ID: 19518005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.